Mohamed Ibrahim Elewaily1, Alyaa R Elsergany2. 1. Mansoura Manchester Medical Program, Faculty of Medicine, Mansoura University, Mansoura, Egypt. mohamed118@stemegypt.edu.eg. 2. Internal Medicine Department, Oncology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Abstract
BACKGROUND: Exosomes are extracellular nanometric vesicles used by cells to communicate with each other. They are responsible for many pathological conditions, including tumors by transferring regulatory biomolecules that impact target cell activity. Because of their high concentration in exosomes compared with parental cells and the rest of exosomal content, specificity to the cell of origin, and their well-organized sorting mechanism, microRNAs (miRNAs) are thought to be the most potent exosomes cargo and used by scientists to track exosomes and to detect cell activity changes and prognosis in cancer early. PURPOSE: In this review, the results of studies examining the role of exosomes in cancer pathophysiology and their clinical potential are discussed in detail. Tumor-derived exosomes (TDEs) mediate the dynamic changes of cancer growth and invasion, including local microenvironment remodeling, distance metastasis, angiogenesis, and tumor-associated immunosuppression. They also contribute to hypoxia-induced tumor progression and cancer cell drug resistance. As a result of exosomes being present in all body fluids, it is possible to have early accessible and less-invasive diagnostic and prognostic measures by forming a table for each cancer type and its matched specific miRNAs. Under testing, available therapeutic uses of exosomes include interference of exosomes biogenesis, secretion, or uptake, and recruitment of exosomes as target-specific drug delivery vehicles, and immunostimulatory agents for both cancer patients and healthy population to avoid cancer development from the start. CONCLUSION: These data suggest that exosomes and exosomal microRNA are directly related to cancer progression mechanisms, and could be used in cancer early diagnosis, prognosis, and therapy.
BACKGROUND: Exosomes are extracellular nanometric vesicles used by cells to communicate with each other. They are responsible for many pathological conditions, including tumors by transferring regulatory biomolecules that impact target cell activity. Because of their high concentration in exosomes compared with parental cells and the rest of exosomal content, specificity to the cell of origin, and their well-organized sorting mechanism, microRNAs (miRNAs) are thought to be the most potent exosomes cargo and used by scientists to track exosomes and to detect cell activity changes and prognosis in cancer early. PURPOSE: In this review, the results of studies examining the role of exosomes in cancer pathophysiology and their clinical potential are discussed in detail. Tumor-derived exosomes (TDEs) mediate the dynamic changes of cancer growth and invasion, including local microenvironment remodeling, distance metastasis, angiogenesis, and tumor-associated immunosuppression. They also contribute to hypoxia-induced tumor progression and cancer cell drug resistance. As a result of exosomes being present in all body fluids, it is possible to have early accessible and less-invasive diagnostic and prognostic measures by forming a table for each cancer type and its matched specific miRNAs. Under testing, available therapeutic uses of exosomes include interference of exosomes biogenesis, secretion, or uptake, and recruitment of exosomes as target-specific drug delivery vehicles, and immunostimulatory agents for both cancerpatients and healthy population to avoid cancer development from the start. CONCLUSION: These data suggest that exosomes and exosomal microRNA are directly related to cancer progression mechanisms, and could be used in cancer early diagnosis, prognosis, and therapy.
Entities:
Keywords:
Cancer clinical potential; Cancer pathophysiology; Cancer treatment; Exosomes; Immunotherapy; MicroRNA
Authors: Marzia Del Re; Elisa Biasco; Stefania Crucitta; Lisa Derosa; Eleonora Rofi; Cinzia Orlandini; Mario Miccoli; Luca Galli; Alfredo Falcone; Guido W Jenster; Ron H van Schaik; Romano Danesi Journal: Eur Urol Date: 2016-10-10 Impact factor: 20.096
Authors: S Rubina Baglio; Tonny Lagerweij; Maria Pérez-Lanzón; Xuan Dung Ho; Nicolas Léveillé; Sonia A Melo; Anne-Marie Cleton-Jansen; Ekaterina S Jordanova; Laura Roncuzzi; Michelina Greco; Monique A J van Eijndhoven; Giulia Grisendi; Massimo Dominici; Roberta Bonafede; Sinead M Lougheed; Tanja D de Gruijl; Nicoletta Zini; Silvia Cervo; Agostino Steffan; Vincenzo Canzonieri; Aare Martson; Katre Maasalu; Sulev Köks; Tom Wurdinger; Nicola Baldini; D Michiel Pegtel Journal: Clin Cancer Res Date: 2017-01-04 Impact factor: 12.531
Authors: Bruno Costa-Silva; Nicole M Aiello; Allyson J Ocean; Swarnima Singh; Haiying Zhang; Basant Kumar Thakur; Annette Becker; Ayuko Hoshino; Milica Tešić Mark; Henrik Molina; Jenny Xiang; Tuo Zhang; Till-Martin Theilen; Guillermo García-Santos; Caitlin Williams; Yonathan Ararso; Yujie Huang; Gonçalo Rodrigues; Tang-Long Shen; Knut Jørgen Labori; Inger Marie Bowitz Lothe; Elin H Kure; Jonathan Hernandez; Alexandre Doussot; Saya H Ebbesen; Paul M Grandgenett; Michael A Hollingsworth; Maneesh Jain; Kavita Mallya; Surinder K Batra; William R Jarnagin; Robert E Schwartz; Irina Matei; Héctor Peinado; Ben Z Stanger; Jacqueline Bromberg; David Lyden Journal: Nat Cell Biol Date: 2015-05-18 Impact factor: 28.824
Authors: Monyse de Nóbrega; Mariana Bisarro Dos Reis; Érica Romão Pereira; Marilesia Ferreira de Souza; Ilce Mara de Syllos Cólus Journal: J Cancer Res Clin Oncol Date: 2022-08-04 Impact factor: 4.322